WO2004090546A1 - Bestimmung eines midregionalen proadrenomedullin-teilpeptids in biologischen flüssigkeiten zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung - Google Patents
Bestimmung eines midregionalen proadrenomedullin-teilpeptids in biologischen flüssigkeiten zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung Download PDFInfo
- Publication number
- WO2004090546A1 WO2004090546A1 PCT/EP2004/000806 EP2004000806W WO2004090546A1 WO 2004090546 A1 WO2004090546 A1 WO 2004090546A1 EP 2004000806 W EP2004000806 W EP 2004000806W WO 2004090546 A1 WO2004090546 A1 WO 2004090546A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proam
- mid
- antibodies
- peptide
- antibody
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Definitions
- the invention relates to methods for the determination of a mid-regional partial peptide of proadrenomedullin (mid-proAM), in particular the 'determination of the proAM (45-92) partial peptide in biological fluids for the purpose of medical diagnosis, in particular in sepsis diagnosis, but also, for example, in cancer diagnosis and cardiac diagnosis or generally in the diagnosis of such disease states in which a determination of the peptide adrenomedullin (AM) provides diagnostically relevant results'.
- the determinations according to the invention are carried out in particular by means of immunoassays of a type in which a labeled antibody is used (sandwich assay; competitive assay according to the SPALT or SPART principle).
- diagnosis is basically used as a simplified generic term, which also includes prognostics / early prognostics and therapy-accompanying treatment should include running control.
- the peptide adrenomedullin was first developed in 1993 by Kitamura et al. As a new 52 amino acid hypotensive peptide isolated from a human phenochromocytoma. (cf. 18; figures refer to the attached list of literature). In the same year, the cDNA coding for a precursor peptide of 185 amino acids and the complete amino acid sequence of this precursor peptide were also described (19; SEQ ID NO: 1). The precursor peptide, which i.a. comprising a signal sequence of 21 amino acids at the N-terminus is referred to as "prepro adrenomedullin" (pre-proAM). In the present description, all amino acid positions indicated normally relate to the pre-proAM comprising 185 amino acids, which has the sequence according to SEQ ID NO: 1, unless the context of the text provides otherwise.
- the peptide adrenomedullin is a 52 amino acid peptide (SEQ ID N0: 2) which comprises amino acids 95 to 146 of the pre-proAM from which it is formed by proteolytic cleavage. Only a few fragments of the peptide fragments formed during the cleavage of the pre-proAM have so far been characterized more precisely, namely the physiologically active peptides adrenomedullin (AM) and "PAMP", a peptide consisting of the 20 amino acids (22-41), which follow the 21 amino acids of the signal peptide in pre-proAM. Both AM and PAMP also discovered and investigated physiologically active subfragments.
- AM is an effective vasodilator, and the hypotensive effect can be attributed to peptide segments in the C-terminal part of AM.
- peptide sequences from the N-terminus of AM show hypertensive effects (cf. e.g. (6)).
- the concentrations of AM that can be measured in the circulation and other biological fluids are significantly higher than those found in healthy control subjects in a number of disease states.
- the AM levels are significant in patients with congestive heart failure, myocardial infarction, kidney diseases, high blood pressure disorders, diabetes mellitus, in the acute phase of a shock and in sepsis and septic shock, albeit to a different extent (see e.g. ( 2), Chapter 7., and the literature cited).
- the PAMP Concentrations are increased in some of the disease states mentioned, although the plasma levels are relatively lower compared to AM ((2); p.1702).
- the pre-proAM SEQ ID NO: 1
- the measurable concentrations of different degradation products of one and the same precursor peptide can be different because they are the result of different competing degradation pathways that, for example, lead to different fragmentation of a precursor peptide and thus to different degradation products in different disease states.
- Certain partial peptides contained in the precursor peptide may or may not be formed as free peptides, and / or different peptides are formed in different ways and in different amounts. Even if only a single degradation path is followed for processing a precursor peptide, and thus all degradation products originate from one and the same precursor peptide and must have originated primarily in equimolar amounts, the stationary concentrations of different partial peptides and fragments that can be measured in biological fluids can be very different , namely, for example, if some of them are formed at different speeds and / or in the have different "individual stabilities " (lifetimes), or if they are removed from the circulation due to different clearance mechanisms and / or with different clearance speeds.
- AM or another of the pre-proAM partial peptides examined so far is not determined for diagnostic purposes, but rather a mid-regional partial peptide which contains the amino acids 42-95 of pre-proAM (SEQ ID NO: 3), where the determination is particularly preferably carried out using an immunoassay in which a labeled antibody is used.
- Claim 1 reflects the essence of the present invention. Advantageous and currently preferred embodiments of the invention can be found in the subclaims.
- a determination method too create that reliably detected the formation of AM or its precursors or by-products in various disease states, in particular sepsis, but also, for example, cardiac diseases, hypertension diseases or cancer diseases or other diseases in which increased AM levels can be observed, despite the rather unpromising results, on the one hand linked to the result of an increased "proadrenomedullin immunoreactivity" described in WO 00/22439.
- additional extensive clinical studies were carried out measuring sera from sepsis, cancer and cardiac patients using various new assays, which surprisingly provided measured values with significantly improved validity.
- Figure 1 shows the results of the measurement of mid-proAM in sera from 109 healthy normal people, compared with the results of the measurement of 110 sera from septic and 20 sera from patients with polytrauma. All measurements were carried out using a SPALT assay as described in more detail in the experimental section. It is noteworthy that - unlike in the case of procalcitonin and other inflammation markers - only the values for the sepsis patients (high concentrations of approx. 550 pmol / 1 or 550 fmol / ml compared to values of 33 pmol / 1 for healthy persons) were increased, but not that Values for polytrauma patients.
- FIG. 2 shows the results of the measurement of mid-proAM in sera from 274 healthy normal persons, from 267 Septikers, from 20 patients with heart diseases and 49 cancer patients using a sandwich assay, as is described in more detail in the experimental part.
- the solid-phase-bound peptide (69-86: peptide region SPCD19; SEQ ID NO: 4) was used as the solid-phase-bound competitor, and a labeled anti-SPCD19 sheep antibody (affinity-enhanced nigt; see experimental part). Served as the standard Dilutions of the peptide SPCD19 in normal horse serum. The detection limit was approx. 50 pmol / 1.
- the pre-proAM species actually occurring in the circulation should be identified and, if necessary, based on their Suitability as a biomarker for routine measurements to be examined ..
- the method thus relates in particular to the determination of the mid-proAM in the circulation of a patient, in particular using plasma samples.
- an assay preferred format in which one works with labeled antibodies, for example an assay which works according to the competitive SPALT principle described above (although other labels, for example radioactive as SPART assay, can also be used).
- Non-competitive sandwich immunoassays have opposite competitive immunoassays, a number 'of advantages, one of which that it can be better designed as a solid-phase assays (heterogeneous assays) may be more robust in the handling, measurement results with a can deliver higher sensitivity and are also better suited for automation and series measurement.
- sandwich immunoassays recognize only those molecules or peptides in which both binding sites for the antibodies used for sandwich formation are on the same molecule available.
- the antibodies can in principle be any suitable monoclonal and / or polyclonal antibodies, although polyclonal antibodies which have been purified from affinity are currently preferred.
- One of the antibodies is particularly preferably obtained by immunizing an animal, in particular sheep, with an antigen which contains a synthetic peptide sequence which contains the amino acids 69-86 of the pre-proAM and an additional cysteine residue at the N-terminus (SEQ ID NO: 4).
- the other antibody can, for example, be obtained accordingly with an antigen which contains a synthetic peptide sequence which Amino acids 83-94 (peptide region PSR13; SEQ ID NO: 5) of the pre-proAM with an additional cysteine residue at the N-Termin ⁇ s.
- the method is carried out as a heterogeneous sandwich immunoassay, in which one of the antibodies is attached to any solid phase, for example the walls of coated test tubes (for example made of polystyrene; coated tubes; CT) or on microtiter plates, for example made of polystyrene. or is immobilized on particles, for example magnetic particles, while the other antibody carries a residue which is a directly detectable label or enables a selective link to a label and serves to detect the sandwich structures formed.
- a delayed or subsequent immobilization using suitable solid phases is also possible.
- the method according to the invention can also be designed as a homogeneous method in which the sandwich complexes formed from the two antibodies and the mid-proAM to be detected remain suspended in the liquid phase.
- Such techniques can be configured in particular as fluorescence amplification or quenching detection methods.
- a particularly preferred method of this type relates to the use of detection reagents to be used in pairs, as described, for example, in US Pat. No.
- EP-Bl-180 492 or EP-Bl-539 477 and the prior art cited therein. They enable a measurement that selectively only detects reaction products that contain both labeling components in a single immune complex, directly in the reaction mixture.
- TRACE ® Time Resolved Amplified Cryptate Emission
- KRYPTOR ® KRYPTOR ®
- the determination method according to the invention can also be carried out particularly advantageously in the context of a so-called multi-parameter diagnosis, both in the field of cardiac diagnosis as well as sepsis and cancer diagnosis.
- Other parameters determined here are, for example, the cardiac parameters ANP, BNP, proANP or proBNP or sepsis parameters, which are selected, for example, from the group consisting of anti-ganglioside antibodies, the proteins procalcitonin, CA 125, CA.
- the invention will hereinafter be described by a description of the preparation of the preferred assay components, the implementation of a preferred embodiment of a sandwich-type assay and the results of mid-proAM determinations in EDTA plasmas of control persons obtained using such an assay, and Sepsis, heart and cancer patients explained in more detail.
- Peptide SPCD19 CRPQDMKGASRSPEDSSPD (SEQ ID N0: 4)
- Peptide PSR13 CSSPDAARI RVKR (SEQ ID NO: 5)
- the peptide-specific antibodies such as were obtained from the antisera which had been obtained beginning with the fourth month after the immunization follows prepared.
- the peptide columns were first washed three times alternately with 10 ml of elution buffer (50 mM citric acid, pH 2.2) and binding buffer (100 mM sodium phosphate, 0.1% Tween, pH 6.8). 100 ml of the sheep antisera were filtered over 0.2 ⁇ m and the existing column material was added. For this purpose, the gel was washed out of the column quantitatively with 10 ml of binding buffer. The incubation was carried out overnight at room temperature with swirling. The batches were transferred quantitatively into empty columns (NAP 25, Pharmacia, emptied). The runs were discarded. The mixture was then washed protein-free with 250 ml of binding buffer (protein content of the wash eluate ⁇ 0.02 A280 nm).
- Elution buffer was added to the washed columns and 1 ml fractions were collected. The protein content of each fraction was determined using the BCA method (see work instructions from PIERCE, Rockford, IL, USA). Fractions with protein concentrations> 0.8 mg / ml were pooled. After protein determination of the pools using the BCA method, yields of 49 mg were found for the anti-SPCD19 antibody (affinity-purified; polyclonal) and 60 mg for the anti-PSR13 antibody (affinity-purified; polyconal).
- chemiluminescent labeling of the antibody 67 ⁇ l of the antibody solution with 10 ⁇ l MA70 acridinium NHS ester ⁇ 1 mg / ml; HOECHST Behring) added and incubated for 15 minutes at room temperature. Then 423 ⁇ l of 1 M glycine were added and incubated for a further 10 minutes. The labeling batch was then buffered over a NAP-5 gel filtration column (Pharmacia) in 1 ml of solvent A (50 mM potassium phosphate, 100 mM NaCl, pH 7.4) and freed from low-molecular constituents in the process.
- solvent A 50 mM potassium phosphate, 100 mM NaCl, pH 7.4
- a gel filtration HPLC (column: Waters Protein Pak SW300) was carried out to remove the last residues of labels not bound to antibodies.
- the sample was applied and chromatographed with mobile phase A at a flow rate of 1 ml / min.
- the wavelengths 280 nm and 368 nm were measured with a flow photometer.
- the absorption ratio 368 nm / 280 nm as a measure of the degree of labeling of the antibody was 0.10 at the peak.
- the fractions containing monomeric antibodies (retention time 8-10 min) were collected and taken up in 3 ml of 100 mM sodium phosphate, 150 mM NaCl, 5% bovine serum albumin, 0.1% sodium azide, pH 7.4.
- the labeled antibody was used on the one hand in a sandwich immunoassay, as will be described in more detail below, but on the other hand also in the SPALT assay already described.
- irradiated 5 ml polystyrene tubes (Greiner company) were coated with purified anti-PSR13 antibody as follows: The antibody was added to 50 mM Tris, 100 mM NaCl, pH 7.8 diluted to a concentration of 6.6 ⁇ g / ml. 300 ⁇ l of this solution were pipetted into each tube. The tubes were incubated at 22 ° C for 20 hours. The solution was suctioned off. Then each tube was filled with 4.2 ml of 10 mM sodium phosphate, 2% Karion FP, 0.3% Bovine Serum Albumin, pH 6.5. After 20 hours the solution was suctioned off. Finally, the tubes were dried in a vacuum dryer. •
- SEQ ID NO: 3 A chemically synthesized mid-proAM (SEQ ID NO: 3) was used as the standard material. This peptide was serially diluted in horse normal serum (SIGMA). Concentrations according to the weight of peptide were ascribed to the standards produced in this way.
- Measurement samples were EDTA plasmas from apparently healthy people, from patients with sepsis and from patients with heart and cancer diseases. 10 ⁇ l standards or samples and 200 ⁇ l assay buffer containing 1 million RLU (relative light units) of the MA70-labeled anti-SPCD19 antibody were pipetted into the test tubes. It was incubated for two hours at 22 ° C. with shaking. The mixture was then washed 4 times with 1 ml of washing solution (0.1% Tween 20) per tube, drained and the chemiluminescence bound to the tube was measured in a luminometer (company BERTHOLD, LB952T; Basisreagenzien BRAHMS AG).
- the solid-phase-bound competitor in the SPALT assay described was the solid-phase-bound peptide SPCD19 (peptide range 69-86; SEQ ID NO: 4), which had been bound to the walls of Polysorb tubes.
- the labeled anti-SPCD19 sheep antibody (affinity-purified) obtained as described under 1. to 4. was used as the antibody. Dilutions of the peptide SPCD19 in normal horse serum served as standard.
- the molar mass of the isolated analyte was determined to be approximately 5146 daltons. This value corresponds to the molar mass of a proAM fragment that contains the amino acids of positions 45-92, i.e. of the mid-proAM, (the theoretical value, assuming that the two methionine residues present are oxidized, is 5146.72 daltons).
- the monoisotopic masses (M + H + ) inter alia identified peptide fragments which correspond to the amino acids of positions 79-89, -75-89, 61-74 and 61-78 of pre-proAM.
- the molecular weight data and the mass spectrometric analysis of the tryptic degradation jointly prove that the peptide contained in the isolated fraction is the peptide designated as mid-proAM (45-92) (SEQ ID NO: 3).
- a determination of the mid-proAM is not subject to any known restrictions due to the existence of a binding protein, fragmentation and weak concentration dynamics.
- the analyte mid-proAM also has good stability, i.e. a very low loss of immunoreactivity when stored at room temperature, which is a great practical advantage for routine diagnostic determinations.
- Tanenao Eto "A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptides (PAMP), hypotensive and vasodilating peptides", Peptides (2001) 22, 1693-1711
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04700013A EP1488209B1 (de) | 2003-04-10 | 2004-01-29 | Bestimmung eines midregionalen proadrenomedullin-teilpeptids in einer biologischen flüssigkeit zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung |
JP2006504400A JP4602321B2 (ja) | 2003-04-10 | 2004-01-29 | 診断目的のための生物学的液体における中間領域プロアドレノメデュリン部分領域の測定およびこのような測定を行うためのイムノアッセイ |
US10/551,298 US9885709B2 (en) | 2003-04-10 | 2004-01-29 | Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination |
CN2004800063452A CN1759319B (zh) | 2003-04-10 | 2004-01-29 | 生物液中肾上腺髓质素原中间区域部分肽在制备免疫诊断剂中的用途 |
DE502004000166T DE502004000166D1 (de) | 2003-04-10 | 2004-01-29 | Bestimmung eines midregionalen proadrenomedullin-teilpeptids in einer biologischen flüssigkeit zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung |
MXPA05010827A MXPA05010827A (es) | 2003-04-10 | 2004-01-29 | Determinacion de un peptido parcial de la region mid de la proadrenomedulina en fluidos biologicos para propositos de diagnostico, e inmunoensayos para la conduccion de una identificacion de este tipo. |
AT04700013T ATE312342T1 (de) | 2003-04-10 | 2004-01-29 | Bestimmung eines midregionalen proadrenomedullin- teilpeptids in einer biologischen flüssigkeit zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung |
HK06109469.7A HK1089232A1 (en) | 2003-04-10 | 2006-08-25 | Use of a midregional proadrenomedullin partial peptide in biological fluids in the production of immological diagnostic agents |
US14/324,620 US9541549B2 (en) | 2003-04-10 | 2014-07-07 | Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination |
US15/869,691 US20180143190A1 (en) | 2003-04-10 | 2018-01-12 | Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10316583.5 | 2003-04-10 | ||
DE10316583A DE10316583A1 (de) | 2003-04-10 | 2003-04-10 | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/551,298 A-371-Of-International US9885709B2 (en) | 2003-04-10 | 2004-01-29 | Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination |
US14/324,620 Continuation US9541549B2 (en) | 2003-04-10 | 2014-07-07 | Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination |
US15/869,691 Continuation US20180143190A1 (en) | 2003-04-10 | 2018-01-12 | Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004090546A1 true WO2004090546A1 (de) | 2004-10-21 |
Family
ID=33038995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/000806 WO2004090546A1 (de) | 2003-04-10 | 2004-01-29 | Bestimmung eines midregionalen proadrenomedullin-teilpeptids in biologischen flüssigkeiten zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung |
Country Status (10)
Country | Link |
---|---|
US (3) | US9885709B2 (de) |
EP (1) | EP1488209B1 (de) |
JP (2) | JP4602321B2 (de) |
CN (1) | CN1759319B (de) |
AT (1) | ATE312342T1 (de) |
DE (2) | DE10316583A1 (de) |
ES (1) | ES2250959T3 (de) |
HK (1) | HK1089232A1 (de) |
MX (1) | MXPA05010827A (de) |
WO (1) | WO2004090546A1 (de) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1620734A1 (de) * | 2003-04-25 | 2006-02-01 | Genova Ltd. | Ausgeschiedene polypeptide mit reduzierter konzentration bei kardiovasculären krankheiten |
WO2007014667A1 (de) | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Aktiengesellschaft | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen |
WO2007062676A1 (en) * | 2005-12-01 | 2007-06-07 | B.R.A.H.M.S. Aktiengesellschaft | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
WO2007144194A1 (de) * | 2006-06-16 | 2007-12-21 | B.R.A.H.M.S Aktiengesellschaft | In vitro multiparameter-bestimmungsverf ahren zur diagnose und frühdiagnose von neurodegenerativen erkrankungen |
US20080213746A1 (en) * | 2006-11-09 | 2008-09-04 | Leong Loke Ng | Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin |
DE102008007218A1 (de) | 2008-02-01 | 2009-08-06 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Indentifizierung von therapiebedürftigen Patienten und zur präventiven Behandlung derartiger Patienten mit leichten kognitiven Störungen |
US20100035275A1 (en) * | 2006-11-08 | 2010-02-11 | Brahms Aktiengesellschaft | Diagnosis and risk assessment of pancreatic diabetes using mr-proadm |
US7915002B2 (en) | 2006-07-24 | 2011-03-29 | B.R.A.H.M.S Gmbh | Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptides |
EP2594587A1 (de) | 2011-11-16 | 2013-05-22 | AdrenoMed AG | Anti-Adrenomedullin-Antikörper (ADM) oder Anti-ADM-Antikörperfragment oder Anti-ADM-Gerüst ohne Ig zur Reduzierung des Sterblichkeitsrisikos bei einem Patienten mit chronischer oder akuter Erkrankung oder in einem akuten Zustand |
EP2594588A1 (de) | 2011-11-16 | 2013-05-22 | AdrenoMed AG | Anti-Adrenomedullin-Antikörper (ADM) oder Anti-ADM-Antikörperfragment oder Anti-ADM-Gerüst ohne Ig zur Verwendung bei der Behandlung |
WO2013072514A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
WO2013072511A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
WO2013072509A1 (en) * | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Adrenomedullin assays and methods for determining mature adrenomedullin |
WO2013072513A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
US8906857B2 (en) | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
WO2018109228A1 (en) | 2016-12-16 | 2018-06-21 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
EP3339324A1 (de) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten |
WO2019053118A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | PROADRÉNOMÉDULLINE AS A MARKER OF ABNORMAL PLATELET RATES |
US10954298B2 (en) | 2011-06-30 | 2021-03-23 | B.R.A.H.M.S. Gmbh | Method of obtaining a binder to prepro-vasopressin or fragments thereof |
US11067586B2 (en) | 2011-11-16 | 2021-07-20 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
US11592450B2 (en) | 2017-08-04 | 2023-02-28 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification of fungal infections |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
CA2633291A1 (en) * | 2005-12-15 | 2007-07-12 | Becton Dickinson And Company | Diagnosis of sepsis |
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
CA3086149A1 (en) | 2006-04-04 | 2007-10-11 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
CN101790687A (zh) * | 2007-08-03 | 2010-07-28 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
JP5607543B2 (ja) * | 2008-02-01 | 2014-10-15 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療に必要な軽度認知障害患者の特定方法とかかる患者の治療剤 |
EP2108958A1 (de) | 2008-04-09 | 2009-10-14 | B.R.A.H.M.S. Aktiengesellschaft | Pro-Endothelin-1 für die Vorhersage eines beeinträchtigten Sauerstoffspitzenverbrauchs |
EP2353011B1 (de) * | 2008-10-07 | 2020-03-04 | B.R.A.H.M.S GmbH | Biomarker zur prognose erster unerwünschter ereignisse |
WO2010054810A1 (en) * | 2008-11-11 | 2010-05-20 | B.R.A.H.M.S Ag | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
US20120129187A1 (en) | 2009-06-16 | 2012-05-24 | B.R.A.H.M.S. Gmbh | Diagnostical use of peroxiredoxin 4 |
JP5827323B2 (ja) * | 2010-06-18 | 2015-12-02 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガン罹患の予測のためのバイオマーカー |
EP2657707A1 (de) * | 2012-04-26 | 2013-10-30 | B.R.A.H.M.S GmbH | Biomarkers zur Diagnose, Vorhersage, Beurteilung und Therapiesynkopenschichtung |
US10598674B2 (en) * | 2013-03-20 | 2020-03-24 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
US11391742B2 (en) | 2015-02-10 | 2022-07-19 | B.R.A.H.M.S. Gmbh | Free histone proteins as biomarkers |
WO2017089474A1 (en) * | 2015-11-27 | 2017-06-01 | Brahms Gmbh | MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT |
CN111065922A (zh) * | 2017-09-13 | 2020-04-24 | B.R.A.H.M.S有限公司 | 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标 |
WO2019053116A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | FLUID THERAPY GUIDING METHOD BASED ON PROADRENOMEDULLINE |
US20220268761A1 (en) * | 2017-10-18 | 2022-08-25 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
EP3502706A1 (de) | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow für risikobewertung und patientenmanagement unter verwendung von procalcitonin und midregional-proadrenomedullin |
EP3608673A1 (de) * | 2018-08-08 | 2020-02-12 | B.R.A.H.M.S GmbH | Pro-adm zur prognose des risikos einer erkrankung, die einen krankenhausaufenthalt bei patienten mit symptomen einer infektionskrankheit erfordert |
CN109613247A (zh) * | 2018-12-22 | 2019-04-12 | 郑州安图生物工程股份有限公司 | 用于检测组织多肽特异性抗原的试剂盒 |
JP7407516B2 (ja) * | 2019-03-26 | 2024-01-04 | 森永乳業株式会社 | 抗原ペプチド検出方法 |
EP3715851A1 (de) | 2019-03-29 | 2020-09-30 | B.R.A.H.M.S GmbH | Verschreibung von fernpatientenmanagement auf der basis von biomarkern |
JP2022526507A (ja) | 2019-03-29 | 2022-05-25 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | バイオマーカーに基づく遠隔患者管理の処方 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000022439A2 (de) * | 1998-10-15 | 2000-04-20 | B.R.A.H.M.S Diagnostica Gmbh | Verfahren und substanzen für die diagnose und therapie von sepsis und sepsisähnlichen systemischen infektionen |
WO2000069900A2 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
GB9211686D0 (en) * | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
DE69509626T2 (de) * | 1994-12-09 | 2000-01-13 | Shionogi & Co | Sandwich-Immunotestverfahren für N-Peptide |
FR2735238B1 (fr) | 1995-06-09 | 1997-09-05 | Cis Bio Int | Utilisation d'un complexe phycobiliproteine-peptide de liaison en tant que traceur fluorescent |
US6440421B1 (en) * | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
US6887470B1 (en) * | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
JP2001011097A (ja) * | 1999-06-29 | 2001-01-16 | Fujirebio Inc | ヒトα1−6フコース転移酵素を認識する抗体、該抗体を用いた免疫測定方法及び試薬 |
WO2001068112A2 (en) * | 2000-03-14 | 2001-09-20 | Goeke Burkhard | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
DE10035706C2 (de) | 2000-07-21 | 2002-11-07 | Brahms Ag | Verfahren zur selektiven Bestimmung von blockierenden Autoantikörpern gegen den TSH-Rezeptor |
JP2004519674A (ja) * | 2001-02-28 | 2004-07-02 | マクギル ユニバーシティ | アモナフィドを用いた個別処置における代謝表現型決定の使用 |
US6884575B2 (en) * | 2001-03-30 | 2005-04-26 | Protemix Corporation Limited | Phosphoprotein target for insulin and its antagonists |
JP2002306164A (ja) * | 2001-04-10 | 2002-10-22 | National Institute Of Infectious Diseases | エボラウイルスを認識するモノクローナル抗体 |
EP1666881B1 (de) * | 2001-05-04 | 2010-02-17 | Biosite Incorporated | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen |
DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
EP1620734A1 (de) * | 2003-04-25 | 2006-02-01 | Genova Ltd. | Ausgeschiedene polypeptide mit reduzierter konzentration bei kardiovasculären krankheiten |
DE102005036094A1 (de) * | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Ag | In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen |
DE102006027818A1 (de) * | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen |
DE102006034142A1 (de) * | 2006-07-24 | 2008-01-31 | B.R.A.H.M.S. Aktiengesellschaft | Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden |
US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
EP2131200A1 (de) * | 2008-06-04 | 2009-12-09 | BRAHMS Aktiengesellschaft | Marker für Transplantatabstossung und Sterblichkeit |
EP2180322A1 (de) * | 2008-10-22 | 2010-04-28 | BRAHMS Aktiengesellschaft | Prognostische Biomarker zur Progression von primär chronischen Nierenerkrankungen |
ES2724478T3 (es) * | 2008-10-24 | 2019-09-11 | Brahms Gmbh | Pronóstico y evaluación del riesgo en pacientes con accidente cerebrovascular determinando el nivel de péptidos marcadores |
CN106153943B (zh) * | 2008-10-31 | 2019-02-15 | B.R.A.H.M.S有限公司 | 用作糖尿病预测生物标志物的精氨酸加压素激素原 |
US9229013B2 (en) * | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
EP2438447B1 (de) * | 2009-06-05 | 2015-02-18 | B.R.A.H.M.S GmbH | Nachweis von bakteriellen Infektionen bei an Dyspnoe leidenden Patienten. |
-
2003
- 2003-04-10 DE DE10316583A patent/DE10316583A1/de not_active Withdrawn
-
2004
- 2004-01-29 CN CN2004800063452A patent/CN1759319B/zh not_active Expired - Lifetime
- 2004-01-29 AT AT04700013T patent/ATE312342T1/de active
- 2004-01-29 JP JP2006504400A patent/JP4602321B2/ja not_active Expired - Lifetime
- 2004-01-29 ES ES04700013T patent/ES2250959T3/es not_active Expired - Lifetime
- 2004-01-29 US US10/551,298 patent/US9885709B2/en active Active
- 2004-01-29 EP EP04700013A patent/EP1488209B1/de not_active Expired - Lifetime
- 2004-01-29 DE DE502004000166T patent/DE502004000166D1/de not_active Expired - Lifetime
- 2004-01-29 MX MXPA05010827A patent/MXPA05010827A/es active IP Right Grant
- 2004-01-29 WO PCT/EP2004/000806 patent/WO2004090546A1/de active IP Right Grant
-
2006
- 2006-08-25 HK HK06109469.7A patent/HK1089232A1/xx not_active IP Right Cessation
-
2010
- 2010-06-02 JP JP2010127350A patent/JP5021791B2/ja not_active Expired - Lifetime
-
2014
- 2014-07-07 US US14/324,620 patent/US9541549B2/en not_active Expired - Lifetime
-
2018
- 2018-01-12 US US15/869,691 patent/US20180143190A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000022439A2 (de) * | 1998-10-15 | 2000-04-20 | B.R.A.H.M.S Diagnostica Gmbh | Verfahren und substanzen für die diagnose und therapie von sepsis und sepsisähnlichen systemischen infektionen |
WO2000069900A2 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1620734A1 (de) * | 2003-04-25 | 2006-02-01 | Genova Ltd. | Ausgeschiedene polypeptide mit reduzierter konzentration bei kardiovasculären krankheiten |
WO2007014667A1 (de) | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Aktiengesellschaft | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen |
JP2009503524A (ja) * | 2005-08-01 | 2009-01-29 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 神経変性疾患の診断のためのinvitro方法 |
US7547553B2 (en) | 2005-08-01 | 2009-06-16 | B.R.A.H.M.S. Aktiengesellschaft | In vitro method for the diagnosis of neurodegenerative diseases |
US20100209433A1 (en) * | 2005-12-01 | 2010-08-19 | B.R.A.H.M.S Aktiengesellschaft | Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
WO2007062676A1 (en) * | 2005-12-01 | 2007-06-07 | B.R.A.H.M.S. Aktiengesellschaft | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
JP2009517670A (ja) * | 2005-12-01 | 2009-04-30 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
US8906857B2 (en) | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
WO2007144194A1 (de) * | 2006-06-16 | 2007-12-21 | B.R.A.H.M.S Aktiengesellschaft | In vitro multiparameter-bestimmungsverf ahren zur diagnose und frühdiagnose von neurodegenerativen erkrankungen |
US7915002B2 (en) | 2006-07-24 | 2011-03-29 | B.R.A.H.M.S Gmbh | Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptides |
US20100035275A1 (en) * | 2006-11-08 | 2010-02-11 | Brahms Aktiengesellschaft | Diagnosis and risk assessment of pancreatic diabetes using mr-proadm |
US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
US20080213746A1 (en) * | 2006-11-09 | 2008-09-04 | Leong Loke Ng | Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin |
DE102008007218A1 (de) | 2008-02-01 | 2009-08-06 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Indentifizierung von therapiebedürftigen Patienten und zur präventiven Behandlung derartiger Patienten mit leichten kognitiven Störungen |
US10954298B2 (en) | 2011-06-30 | 2021-03-23 | B.R.A.H.M.S. Gmbh | Method of obtaining a binder to prepro-vasopressin or fragments thereof |
US9140696B2 (en) | 2011-11-16 | 2015-09-22 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
US10227405B2 (en) | 2011-11-16 | 2019-03-12 | Adrenomed Ag | Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment |
WO2013072513A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
WO2013072512A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
WO2013072511A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
WO2013072510A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
WO2013072514A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
US9304127B2 (en) | 2011-11-16 | 2016-04-05 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy |
US9402900B2 (en) | 2011-11-16 | 2016-08-02 | Adrenomed Ag | Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody |
US9535060B2 (en) | 2011-11-16 | 2017-01-03 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
EP2594588A1 (de) | 2011-11-16 | 2013-05-22 | AdrenoMed AG | Anti-Adrenomedullin-Antikörper (ADM) oder Anti-ADM-Antikörperfragment oder Anti-ADM-Gerüst ohne Ig zur Verwendung bei der Behandlung |
RU2657517C2 (ru) * | 2011-11-16 | 2018-06-14 | Сфинготек Гмбх | Анализ адромедуллина и способы определения зрелого адромедуллина |
US11726101B2 (en) | 2011-11-16 | 2023-08-15 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
US11673949B2 (en) | 2011-11-16 | 2023-06-13 | Adrenomed Ag | Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM |
US10221238B2 (en) | 2011-11-16 | 2019-03-05 | Adrenomed Ag | Method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adranomedullin (ADM) activity by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment to the subject |
WO2013072509A1 (en) * | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Adrenomedullin assays and methods for determining mature adrenomedullin |
EP4086283A1 (de) | 2011-11-16 | 2022-11-09 | AdrenoMed AG | Anti-adrenomedullin (adm)-antikörper oder anti-adm-antikörperfragment oder anti-adm-non-ig-gerüst zur verhinderung oder linderung einer organdysfunktion oder eines organversagens bei einem patienten mit einer chronischen oder akuten krankheit oder einem akuten leiden |
EP3553084A1 (de) | 2011-11-16 | 2019-10-16 | AdrenoMed AG | Anti-adrenomedullin (adm)-antikörper oder anti-adm-antikörperfragment oder anti-adm-non-ig-gerüst zur verhinderung oder linderung einer organdysfunktion oder eines organversagens bei einem patienten mit einer chronischen oder akuten krankheit oder einem akuten leiden |
US10800842B2 (en) | 2011-11-16 | 2020-10-13 | Adrenomed Ag | Anti-adrenomedullin (ADM) monoclonal antibodies and anti-ADM monoclonal antibody fragments that bind to adrenomedullin |
EP2594587A1 (de) | 2011-11-16 | 2013-05-22 | AdrenoMed AG | Anti-Adrenomedullin-Antikörper (ADM) oder Anti-ADM-Antikörperfragment oder Anti-ADM-Gerüst ohne Ig zur Reduzierung des Sterblichkeitsrisikos bei einem Patienten mit chronischer oder akuter Erkrankung oder in einem akuten Zustand |
US11067586B2 (en) | 2011-11-16 | 2021-07-20 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
WO2018109228A1 (en) | 2016-12-16 | 2018-06-21 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
EP3339324A1 (de) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten |
US11592450B2 (en) | 2017-08-04 | 2023-02-28 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification of fungal infections |
EP3971572A1 (de) * | 2017-09-13 | 2022-03-23 | B.R.A.H.M.S GmbH | Proadrenomedullin als marker für anormale thrombozytenspiegel |
EP3971573A1 (de) * | 2017-09-13 | 2022-03-23 | B.R.A.H.M.S GmbH | Proadrenomedullin als marker für anormale thrombozytenspiegel |
US11327082B2 (en) | 2017-09-13 | 2022-05-10 | B.R.A.H.M.S Gmbh | Proadrenomedullin as a marker for abnormal platelet levels |
WO2019053118A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | PROADRÉNOMÉDULLINE AS A MARKER OF ABNORMAL PLATELET RATES |
US12000845B2 (en) | 2017-09-13 | 2024-06-04 | B.R.A.H.M.S Gmbh | Method for discharging a patient from an intensive care unit |
Also Published As
Publication number | Publication date |
---|---|
DE502004000166D1 (de) | 2006-01-12 |
US20180143190A1 (en) | 2018-05-24 |
ATE312342T1 (de) | 2005-12-15 |
JP2006523302A (ja) | 2006-10-12 |
EP1488209A1 (de) | 2004-12-22 |
CN1759319A (zh) | 2006-04-12 |
JP5021791B2 (ja) | 2012-09-12 |
MXPA05010827A (es) | 2006-03-09 |
JP4602321B2 (ja) | 2010-12-22 |
US20070212742A1 (en) | 2007-09-13 |
US9541549B2 (en) | 2017-01-10 |
EP1488209B1 (de) | 2005-12-07 |
US20140322822A1 (en) | 2014-10-30 |
DE10316583A1 (de) | 2004-10-28 |
ES2250959T3 (es) | 2006-04-16 |
JP2010210644A (ja) | 2010-09-24 |
HK1089232A1 (en) | 2006-11-24 |
US9885709B2 (en) | 2018-02-06 |
CN1759319B (zh) | 2011-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1488209B1 (de) | Bestimmung eines midregionalen proadrenomedullin-teilpeptids in einer biologischen flüssigkeit zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung | |
EP2111552B1 (de) | Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm | |
EP1562984B1 (de) | Sandwich-immunoassay zur bestimmung von proanp-teilpeptiden | |
EP2147316B1 (de) | Diagnose und risikostratifizierung mittels nt-proet-1 | |
EP2084543B1 (de) | Risikostratifizierung des akuten koronarsyndroms mittels fragmenten / teilpeptiden des provasopressins, insbesondere copeptin oder neurophysin ii | |
WO2005078456A1 (de) | Verfahren zur bestimmung der bildung von endothelinen zu zwecken der medizinischen diagnostik, sowie antikörper und kits für die durchführung eines solchen verfahrens | |
DE102007009751A1 (de) | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens | |
DE102007022367A1 (de) | Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten | |
DE602004013135T2 (de) | Verfahren für die Diagnose von schwerkranken Patienten | |
EP1497662B1 (de) | Verwendungen der carbamoylphosphat synthetase 1 (cps 1) und ihrer fragmente für die diagnose von sepsis | |
DE102005011421A1 (de) | Bestimmung von kurzkettiger SRL-Alkoholdehydrogenase (DHRS4) als Biomarker für Entzündungen und Infektionen | |
DE10082504B4 (de) | Verfahren, Immunoassay und Kit zur Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen | |
EP1493034B1 (de) | Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1 | |
DE69219451T2 (de) | Einschätzung der Beinzerbrechlichkeit und Voraussage osteoporotischer Bruchaussicht unter Verwendung einer quantitativen Bestimmung zirkulierendes unterkarboxyliertes Osteokalzin | |
DE102005057920A1 (de) | Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben | |
EP1425588B1 (de) | Bestimmung der wirksamen parathormon-aktivität in einer probe | |
AT407674B (de) | Verfahren zur bestimmung von atrialem natriuretischem peptid (anp) | |
DE602005000636T2 (de) | Verfahren zur Auswertung des Knorpelgewebeabbau | |
DE69333683T2 (de) | Antikörper-testbesteck zur bestimmung von amylin | |
DE102006050497A1 (de) | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II | |
DE102006057409A1 (de) | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II | |
EP1651961A1 (de) | Biochemisches diagnostikum zur erkennung von rheumatoider arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2004700013 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2004700013 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048063452 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007212742 Country of ref document: US Ref document number: 10551298 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/010827 Country of ref document: MX Ref document number: 2006504400 Country of ref document: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004700013 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10551298 Country of ref document: US |